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Brief Research Summary (PAO): Bisphosphonates as a Countermeasure to Space Flight Induced Bone 
Loss (Bisphosphonates) will determine whether antiresorptive agents, in conjunction with the routine in-
flight exercise program, will protect ISS crewmembers from the regional decreases in bone mineral 
density documented on previous ISS missions. 
https://ntrs.nasa.gov/search.jsp?R=20090014795 2019-08-30T06:35:08+00:00Z
 
Research Summary:  
• The potential for loss of bone mass is one of the most important medical concerns for long- 
duration manned space flight with regional losses of 1-2% per month in spite of the fact that 
crewmembers exercise while in space. The resultant hypercalciuria increases the risk of renal 
stone formation.  
• Bisphosphonates are a group of antiresorptive agents that block breakdown of bone and are used 
to treat osteoporosis and other disorders related to bone turnover. 
• This study will test the effectiveness of two bisphosphonates; alendronate, taken as a pill once 
per week before and during space flight; and zoledronic acid, given by intravenous infusion once 
before flight with an effect lasting for the length of the flight. 
• If shown to be an effective countermeasure to space flight-induced bone loss, bisphosphonates 
or other antiresorptive agents could help prevent several bone-related problems for 
crewmembers on ISS and on future long-duration missions. These problems include loss of bone 
mineral mass and the possibility of developing renal stones during or after space flight. 
Detailed Research Description:   
The purpose of this investigation is to determine whether bisphosphonates, in conjunction with the routine 
in-flight exercise program, will protect ISS crewmembers from the regional decreases in bone mineral 
density documented on previous ISS flights. Two dosing regimens will be tested: (1) an oral dose of 70 
mg of alendronate taken weekly starting 3 weeks prior to flight and then throughout the flight and (2) an 
I.V. dose of zoledronic acid, 4 mg, administered just once approximately 45 days before flight. The 
rationale for including both alendronate and zoledronic acid is that two dosing options will: maximize crew 
participation, increase the countermeasure options available to flight surgeons, increase scientific 
opportunities, and minimize the effects of operational and logistical constraints. Operational and logistical 
constraints may favor one option versus the other. The purpose of this study is not to test one dosing 
option versus the other. Rather, the intent is to show that bisphosphonates plus exercise will have a 
measurable effect versus exercise alone in preventing space flight-induced bone loss. 
 
The primary measurement objective of this study will be to obtain preflight and postflight Quantitative 
Computed Tomography (QCT) scans of the hip. The QCT scans will provide volumetric bone density 
information of both cortical and trabecular (spongy) bone regions of the hip. This study aims to show that 
bisphosphonates will significantly reduce bone mineral density loss and the increased risk of renal stone 
formation documented previously on untreated ISS crewmembers. 
 
Secondary measurement objectives will include: preflight and postflight Dual-energy X-Ray 
Absorptiometry (DXA) scans of the whole body, spine, hip, and heel; preflight and postflight scans of the 
tibia using peripheral Quantitative Computed Tomography (pQCT); preflight and postflight blood draws to 
measure serum markers of bone metabolism, and preflight, inflight, and postflight urine collections to 
measure urinary markers of bone metabolism. Urine measurements will also be used to look at the risk 
for developing renal stones before, during and after flight. 
 
Project Type: Payload 
 
Images and Captions: 
 
One mm thick sections through the mid frontal plane of the hip, showing regions of evaluation in white superimposed on a false color image of the 
Quantitative Computed Tomography (QCT) data. The left hand image shows the cortical region of the femoral neck and the right hand image shows 
the trabecular bone regions. Courtesy image of NASA. 
 
Operations Location: ISS Inflight 
 
Brief Research Operations:  
• While in flight, Alendronate subjects will ingest a pill weekly. 
• All subjects will conduct three urine collection sessions. 
 
Operational Requirements: This experiment requires the participation of 10 long duration 
crewmembers. Subjects will complete DXA and pQCT Scans (L-45, R+5, R+180, and R+360, R+720, 
R+1080), High Resolution QCT scans (L-45, R+5, R+360), 24-hr urine collections (L-90, L-10, R+0, 
R+14, R+30, R+180, R+360), and blood draws (L-90, L-10, R+0, R+14, R+30, and R+180, R+360). 
Alendronate subjects will complete an Alendronate Tolerance Test on L-180, and they will take 
Alendronate on L-17, L-10, and L-3. Zoledronic Acid subjects will be administered the bisphosphonate on 
L-45 and will conduct one or more additional blood draws for post-infusion health monitoring. 
 
Operational Protocols: While in flight, Alendronate subjects will ingest a pill weekly. All subjects will 
conduct three urine collection sessions (flight day 4 weeks, 12 weeks, and 24 weeks). Crewmembers will 
also take a daily Vitamin D supplement during the duration of the mission. 
 
Category: Human Research and Countermeasure Development for Exploration 
 
Subcategory: Bone and Muscle Physiology in Space 
 
Space Applications: The purpose of this investigation is to determine whether antiresorptive 
bisphosphonates, in conjunction with the routine in-flight exercise program, will protect ISS crewmembers 
from the regional decreases in bone mineral density documented on previous ISS flights. If shown to be 
an effective countermeasure to space flight-induced bone loss, bisphosphonates could prevent or 
ameliorate several potential bone-related problems identified in NASA’s Critical Path Roadmap. If 
bisphosphonates improve the efficiency of in-flight exercise to maintain bone mass, then more crew time 
could be made available to ameliorate other problem areas. 
 
Earth Applications: The benefits of this research are primarily for space travelers. Knowledge gained 
from this investigation may generate useful information applicable to patients on Earth with accelerated 
bone loss due to disuse (e.g., spinal cord injury patients or those with prolonged immobilization). The 
timeframe required for relevant knowledge to be transferred to the medical community at large would be 
an estimated 4-6 years. 
 
Manifest Status: Planned 
 
Availability: Developed for ISS  
 
 
Supporting Organization: Exploration Systems Mission Directorate (ESMD)  
 
Previous Missions: Bisphosphonates is a unique investigation that has not been conducted in 
microgravity. 
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